Republic Republic Republic
  • Log in
Oops! We couldn’t find any results...
Can’t find a deal? Try advanced search.
Is something missing? Add your suggestion here.
Primary market Live deals Secondary market Buy and sell Republic Note Own a piece of Republic's upside Investor Network Membership Receive exclusive discounts and benefits
Republic Venture Opportunities for accredited investors
Republic Capital Multi-stage venture firm Republic Digital Crypto hedge fund
Wallet Manage your digital assets Mobile app Available on iOS or Android Learning center Explore investor resources FAQ Get your questions answered
Capital fundraising Raise on Republic Tokenized assets Design, launch, manage tokenized assets Sharedrops Gift equity as a reward
Advisory Access veteran web3 advisors Infrastructure Stake your digital assets Tokenization Deploy your assets on-chain Asset management Explore digital asset funds
Republic Capital In-house Venture Capital fund Broker dealer Regulated capital services
Log in Sign up

Republic Republic Republic
Oops! We couldn’t find any results...
Can’t find a deal? Try advanced search.
Is something missing? Add your suggestion here.
  • US
  • Log in
  • Sign up
All investors
Primary market Live deals Secondary market Buy and sell Republic Note Own a piece of Republic's upside Investor Network Membership Receive exclusive discounts and benefits
Accredited only
Republic Venture Opportunities for accredited investors
Institutional
Republic Capital Multi-stage venture firm Republic Digital Crypto hedge fund
More
Wallet Manage your digital assets Mobile app Available on iOS or Android Learning center Explore investor resources FAQ Get your questions answered
Spotlight deal
Hamilton Lane Private Infrastructure Fund
Hamilton Lane Private Infrastructure Fund
Get unique access to the full spectrum of private markets with Hamilton Lane
Growth capital solutions
Capital fundraising Raise on Republic Tokenized assets Design, launch, manage tokenized assets
Sharedrops Gift equity as a reward
Web3 services
Advisory Access veteran web3 advisors Infrastructure Stake your digital assets Tokenization Deploy your assets on-chain Asset management Explore digital asset funds
Institutional services
Republic Capital In-house Venture Capital fund
Broker dealer Regulated capital services

Canopy isn't accepting new investments

Canopy’s deadline was July 1, 2021

Follow the company to stay updated on their progress, including future investment opportunities


Explore new investment opportunities:
View companies raising now
Campaign ended
Logo of Canopy

Canopy

The next generation, reusable respirator — for the world’s well-being
B2C B2B Healthcare Facilities & Equipment Fight Disease
Facebook Telegram Twitter LinkedIn
Featured image of Canopy
$325,469
Raised
723
Investors
Successfully funded and closed on July 1, 2021.
Invest in Canopy

Open for investment

Investors in Canopy also invested in these companies. View more
Logo of Eli Roth's The Horror Section

Eli Roth's The...

A brand-new independent studio from an iconic horror...

Republic Funding Portal · Reg CF
Loading...
Pitch Updates 14 Reviews 161
Invest Invest in Canopy
Facebook Telegram Twitter LinkedIn
Closed on July 1, 2021. Information may not be up-to-date. Campaign closed on July 1, 2021. Information displayed may not be up-to-date.
Problem Solution Product Traction Customers Biz. model Market Competition Vision and strategy Funding Founders
About Team Press

Documents

Republic (OpenDeal Portal LLC, CRD #283874) is hosting this Reg CF securities offering by Grove Biomedical LLC. View the official SEC filing and all updates:
Official SEC Logo Form C SEC.gov
Company documents
Canopy IPA Canopy Form C:A.pdf Canopy Form C.pdf
Loading

Hear from some of the 723 investors in Canopy


Show more

Highlights


  • Patent-pending, transparent respirator system solves N95 flaws
  • Shipping in Q1 '21. Saves hospitals >50% on PPE; quickly pays for itself
  • Led by Google, Johns Hopkins, DaVita, Boston Scientific & Pall alumni
  • Strong unit economics, razor / blade model & lean cost structure
  • >$1B annual enterprise pipeline managed by med-device sales veterans
  • Upcoming pilot with Northwell, New York's largest health system
  • Little true competition despite high demand for a reusable N95 replacement

Problem


Catastrophic global shortage of the N95 respirator: an expensive, uncomfortable and wasteful half-century-old design

Every day, healthcare professionals and frontline workers have to deal with Personal Protective Equipment (PPE) that gets in the way of their comfort, their breathing, and their communication. Disposable N95 respirators currently on the market date back to the 1960's, irritate skin, fog up glasses, force re-breathing of toxic carbon dioxide and create barriers between essential workers and their patients and customers. Not to mention, these devices create over 100,000 tons of landfill waste per year and can cost hospitals over $1,000 per employee annually.

We deserve better.  

Solution


Meet Canopy: The supremely comfortable, transparent, reusable, and affordable N95 alternative

Since late March 2020 a team of entrepreneurs, material scientists, biomedical engineers, industrial designers, clinicians, hospital administrators, and former FDA officials has been quietly working to develop and commercialize Canopy, the next-generation reusable respirator. Canopy is led by alumni from top research institutions and innovation hubs including:

(Canopy is not affiliated with, nor endorsed by, the above institutions)

Shipping in Q1 2021, every aspect of Canopy was developed based on direct feedback from healthcare professionals and frontline workers. Over the past seven months our team of Johns-Hopkins-trained biomedical engineers and former Nike industrial designers brought the concept to life. 

Finally, Canopy built a supply chain of some of the world's largest, most sophisticated medical device and filtration contract manufacturers and logistics providers to rapidly deploy Canopy on a mass-scale.

Canopy’s patent-pending system solves for the top shortcomings of current N95 respirators. Most importantly, Canopy's novel filter design doesn't use globally-scarce meltblown textiles. 

  • Cost: Substantially reduced total cost of ownership can save hospitals thousands of dollars per year per employee compared to disposable N95s
  • Availability: Canopy does not rely on globally-scarce meltblown filters, and has partnered with the world's largest sterile air filter OEM to manufacture our proprietary filtration solution
  • Comfort: Silicone face seal does not cause skin abrasions

  • Breathability: Canopy’s novel, proprietary filter has 3x the surface area of a disposable N95

  • Communication: Canopy is transparent, enabling lip-reading and smiling

  • Waste: Converting to Canopy eliminates up to 100 lbs. of annual landfill waste per user

  • Durability: Canopy is sterilizable, dishwasher safe, and can be sanitized with any hospital-grade disinfectant wipe

  • Safety: Canopy is a 'half-face' respirator with a seal that goes under the chin and has wings that cover the cheeks, enabling talking/smiling vs. less reliable 'quarter-face' competitors that rest on the chin and run the risk of a broken seal when talking or smiling.

Product


Clinician-designed, hospital-grade respirator with proprietary replacement filter

                           

Shipping in Q1 2021, every aspect of Canopy was developed based on direct feedback from healthcare professionals and frontline workers. Over the past seven months our team of Johns-Hopkins-trained biomedical engineers and former Nike industrial designers brought the concept to life. Finally, Canopy built a supply chain of some of the world's largest, most sophisticated medical device and filtration contract manufacturers and logistics providers to rapidly deploy Canopy on a mass-scale.

Your browser does not support HTML5 video.

Patent-pending filter: Designed by a team with over 100 patents in medical filtration, Canopy’s radially-pleated, patent-pending filter has 3x the surface area of a standard N95, giving users the space to breathe easily. Importantly, Canopy’s filter does not rely on electrostatically-charged meltblown filters. Our raw materials are not in short supply.

Up to 99.8% filtration efficiency under certain conditions in third-party testing conducted by Drs. Rob MacCuspie, Cary Hill and Matthew Hull at NanoSafe, Inc.

Transparent front lens: Canopy’s transparent front lens and permanent anti-fog coat means users can interact with patients, customers, friends, and family in a way that allows them to see and be seen, express empathy, smile, and communicate effectively.

Biocompatible silicone seal: Canopy's form-fitting silicone seal is soft on the skin and snug on the face, guarding users from exposure without leaving “bridge of honor” skin abrasions behind. Each respirator also comes with easy-to-adjust neck straps and a headpiece so comfortable users forget it’s there.


Durable yet comfortable materials: Canopy is made from durable, high-performance polymers that are simple to wipe down with common disinfectants, enabling easy cleaning and sustainable re-use.

Mass-scale US based supply chain: All but two of Canopy’s components are made in the United States and assembled at one of the country's largest ISO 13485 / 9001 medical contract manufacturing facilities.

No metal parts: Canopy can be worn anywhere in the hospital, even near X-Ray and MRI machines.

Utility Patent: Canopy was accepted into the USPTO's COVID "TrackOne" fast track program. We've received our office action / response and will be receiving a full patent in mid 2021.

Customization: Corporate branding and custom colors available by request.


Product Roadmap: Canopy has developed working prototypes of  a consumer-grade respirator variant along with a line of interchangeable filters that can be stockpiled for Chemical, Biological, Radiological and Nuclear hazards. We’ve also begun R&D and partnerships work for virus-detecting and virucidal filters.

Short term roadmap:

  • Integrated face shield (ETA Q1 2021)
  • Fabric strapping system (ETA Q1 2021)
  • White-labeled, branded cleaning solutions (wipes, tablets, sprays)
  • Full suite of interchangeable N, P, & R rated filters for CBRN hazard stockpiling

Traction


Fulfilling initial shipments and launching hospital pilots in Q1 2021

While operating in stealth mode, Canopy has completed tooling and validation testing,  has signed multi-year agreements with some of the world's largest OEM medical device and filtration manufacturers. Our supply chain and global fulfillment infrastructure is ready to begin fulfilling orders in January.  Canopy can fulfill $50MM in 2021 order volume without making additional capital investment in production or fulfillment infrastructure.

Northwell Health, New York’s largest health system, will lead an evaluation comparing Canopy against incumbent disposable N95s to demonstrate key benefits such as comfort, breathability, patient experience and economic value. Northwell’s Emergency Medicine Research Consortium developed the protocol in collaboration with the Canopy team. 

“Given the significant limitations, drawbacks and shortages of existing PPE, we are eager for our staff to begin testing Canopy in the clinical setting. It cannot come soon enough.” --Dr. Yves Duroseau MD MPH, Chief of Emergency Medicine at Lenox Hill Hospital, part of Northwell Health.

Canopy is also working with researchers at Emory University to evaluate the impact of clear respirators on patient anxiety levels.

Prior to officially launching we’ve received tremendous inbound interest, sample requests and purchase requests from hospital procurement officers, epidemiologists, doctors, nurses, medical leaders, and government officials from institutions including:

Canopy has entered into a strategic partnership with a Access Strategy Partners, Inc. (ASPI), a sales organization led by executive-level veterans from both the buy and sell side of the healthcare procurement market. The ASPI collectively has billions of dollars worth of medical device sales and purchasing experience, and will be leading our enterprise healthcare sales strategy.

In addition to our enterprise sales, Canopy's product suite will be available through our owned and operated e-commerce website, and Canopy "Starter Kits" will be available on across mass-distribution platforms including:

Customers


Taking care of the people who take care of us

Canopy was created in response to a mass shortage of N95 respirators at the onset of COVID-19. Relying on the expertise of healthcare professionals, we designed Canopy so that anyone on the front lines can do their job without the fear of putting themselves or their loved ones at risk. 

For those of us who don’t work on the front lines, we too have seen the benefits of having a comfortable and reusable mask to protect ourselves, and the people we love, from fast-spreading illness, wildfire smoke, and poor air quality.

Business model


Hybrid B2B & B2C strategy with recurring subscription  

The Canopy team has developed a highly capital-efficient operating model that ensures product and operational excellence through strategic partnerships with best-in-class sales, mass-scale contract manufacturing, third-party logistics and back-office service providers. These partnerships are structured primarily on a variable cost or commission basis, allowing Canopy to remain lean while ensuring supply chain stability and that the resources to support rapid growth are available on demand.

As a company founded in response to the COVID-19 Pandemic, Canopy is not saddled with traditional overhead such as office leases or large travel budgets. Our profitable unit-economics yield strong contribution margins at all sales volumes, and our razor / razor-blade model ensures recurring revenue streams across customer segments.

We expect to become cash flow positive and to begin making initial distributions to investors in 2021, while maintaining a sufficient capital position to meet demand and fuel growth in the form of strategic product roadmap development and geographic expansion.

Subscription Model: Enterprise customers receive preferred pricing with high volume orders and annual supply agreements to ensure constant PPE compliance. Online self-purchasers can replenish filters as desired or sign up for subscribe-and-save auto-renewals.

Multi-channel fulfillment Operations: Our high-volume, low-defect fulfillment network was built for modern, multi-channel commerce. Inventory pooling means all sales channels leverage the same warehouse inventory, with real-time availability, nationwide 2-day ground shipping coverage and AI-based forecasting / replenishment. 

Market


A $17B+ market 

With the mass shortage of N95 respirators, we stand to capture a meaningful share of a >$17B market. Beyond the immediate pandemic-related need, institutional buyers are in the market to convert away from disposable respirators to reusable solutions. 

While incumbent disposable supply has been steadily increasing to meet demand, a desire to convert away from disposables, matched with few reusable alternatives, creates a major opportunity for Canopy.

Canopy's novel filter design doesn't use globally-scarce meltblown textiles. Every other attempt to design a new mask still calls for the same, unavailable raw material already used in traditional N95s.

Canopy expects to be the first NIOSH-certified reusable respirator designed specifically for medical professionals, and the first new reusable respirator design approved by NIOSH since the pandemic began.

Competition


Desire to abandon disposable N95s met with few reusable alternatives

The team at Canopy worked with healthcare professionals to create a respirator that solves for all the pain points of current N95 respirators. 

According to recent news reports, Canopy's closest competitor, Envo Mask, introduced their device in Q4 2019 and is selling 1600-2000 units per day. At MSRP, that represents a $46MM - $58MM annual run rate. Canopy's design solves for all of the Envo Mask shortcomings. And ClearMask, a transparent disposable non-N95 surgical mask, is on track to hit $40MM of sales in 2020.

Vision and strategy


Creating sustainable products that increase comfort, safety, and performance

Canopy is the next generation respirator, but it’s also so much more. It’s a pledge we can each make to the well-being of the people and places we love.

Beyond the initial respirator, Canopy’s mission is to protect the world’s well-being by creating sustainable products that increase comfort, safety, and performance. We are exploring additional opportunities to replace single-use products in the clinical setting with superior-performance, more economically efficient alternatives while simultaneously reducing waste. 

We’re proud to be a certified B Corporation pending, the highest rating a company our age (less than 12 months) can achieve, and Canopy sales directly address 9 of the 17 UN sustainable development goals. Our forthcoming 501(c)(3) nonprofit, ‘One Canopy,’ will partner with leading NGOs, governments, and public health organizations to distribute Canopy respirators to populations in need, domestic and abroad.

Funding


Capital raise of $1M

To date, we’ve built Canopy exclusively with founder capital from Grove North Ventures, our founder and CEO's investment vehicle. 

To supplement our investment, Canopy is raising up to $1.07M to:

  • Accelerate sales and marketing initiatives
  • Build inventory for rapid fulfillment 
  • Launch multi-channel paid media campaign
  • Pursue product roadmap
  • Expand sales and marketing team to support demand

With the current raise, we’ll be able to achieve positive cash flow and set in-motion a substantial inventory build, enabling us to quickly fulfill orders and get Canopy into the hands of those frontline workers who need it most.

Founders


Meet our founder & CEO Joe Rosenberg

Canopy was created by scientists, industrial designers and healthcare professionals who have studied and worked at leading research institutions and innovation centers.

From 2010-2018, Joe was intimately involved in Google’s efforts to revolutionize retail e-commerce, leading the partnership development and management strategy for projects including Google Express and Purchases on Google. He’s partnered with the country’s largest retailers to build innovative business growth strategies.

Joe has created first-of-their-kind partnership deals between Google and organizations in both the retail and financial services industries, including negotiating agreements impacting more than $1B of Google e-commerce transaction volume.

In May 2018 Joe founded Grove North Ventures. Grove provides business incubation and acceleration services, specializing in e-commerce business development. It helps to bring innovative companies and products to the world, building their infrastructure, cultivating strategic partnerships, and developing go-to-market strategies to enable growth early in a company or product lifecycle. Joe frequently advises large companies and top-tier consulting and investment firms in the e-commerce and retail industries as well as on digital transformations. Joe earned a BA with honors from the Gallatin School at NYU in 2010, and is the co-founder of Subject to Change Wine Company, a natural winery in California.

__

A Singapore native, QX was awarded the prestigious Defense Science and Technology Scholarship in 2009 by the Singapore government. After graduating with top honors in 2013 from Johns Hopkins University with a B.S in Biomedical Engineering and MSE in Bioengineering Innovation and Design, QX returned to Singapore to work at DSO National Laboratories, Singapore's national defense research lab.

During his 6-year tenure at DSO, QX specialized in soldier performance, developing products such as the patented A-Lite backpack, which reduced soldier fatigue by properly distributing heavy loads. The backpack received the company's Innovation award, and is currently standard-issue for the Singapore Army.

QX’s team drove DSO’s product development strategy. For his work in shaping the workflow and user interface for the Xentinel counter-drone vehicle, QX was awarded the KINETIC award, the company’s highest internal award.

__

Prior to joining Canopy, Doug spent five years in Operations Innovation management at DaVita, Inc., solving the company’s most pressing process & operations challenges. Doug's work included restructuring and streamlining the customer service model for DaVita's in-house pharmacy, developing and implementing a new electronic health records system to drive enhanced dialysis outcomes, and addressing process and documentation issues that were inhibiting Home Dialysis programs from full billings. Doug's efforts contributed to over $20M annual operational cost reductions, as well as significant improvements to work culture and employee satisfaction.

While at DaVita, Doug also had a leading role in sustainability work on the headquarters campus, and led a team focused on waste reduction to realize sustainable 15% reduction in total waste over two years.

__

Kim currently serves as Senior Vice President, Head of Pension Risk Transfer (PRT) at Athene and is responsible for the management and growth of the company’s PRT business. 

Prior to joining Athene, Kim served as Vice President, Head of Distribution & Retirement Solutions for Legal & General’s US PRT business. As a founding member of the business in 2015, Kim led sales, marketing, client solutions and business strategy, growing the business to nearly $4 billion in assets. She previously served as the Deputy Head of Distribution for Legal & General’s US investment business where she worked with corporate pension and insurance clients to implement Liability Driven Investment and fixed income strategies.

Prior to Legal & General, she served as a Director with Cutwater Asset Management, where she helped transform Cutwater to a pension risk management business post-financial crisis where she led the development of pension de-risking strategies and insurance solutions for institutional clients. Kim also led asset-liability management for Cutwater’s $30 billion spread-lending business and held risk roles focused on market risk, hedging, and liquidity management.    

A recognized leader in the pension industry, Kim was named to LIMRA’s Rising Stars in Retirement Under 40 List and has published numerous research pieces on pension risk management.

Kim holds a BBA in public accounting and an honors degree from the Pforzheimer Honors College at Pace University where she graduated magna cum laude.  She also holds an MBA from Marist College. 

Deal terms


Minimum investment

$100.98

The smallest investment amount that Canopy is accepting.
Learn more

Funding goal

$1.07M

Canopy must achieve its minimum goal of $25K before the deadline. The maximum amount the offering can raise is $1.07M.
Learn more

Deadline
Canopy needs to reach their minimum funding goal before the deadline ( ). If they don’t, all investments will be refunded.
Learn more
Type of security

Crowd IPA

Crowd IPA (Interests Purchase Agreement) is a simple agreement to acquire membership units of a limited liability company.
Learn more

Valuation

$6,500,000

The stated valuation of the company before any subscriptions are taken in to account. Each dollar invested in Canopy will increase the valuation by that same amount, assuming the offering is successful.
Learn more

Price per security

$5.61

The price of each membership unit.
Learn more

How it works

Documents

Republic (OpenDeal Portal LLC, CRD #283874) is hosting this Reg CF securities offering by Grove Biomedical LLC. View the official SEC filing and all updates:
Official SEC Logo Form C SEC.gov
Company documents
Canopy IPA Canopy Form C:A.pdf Canopy Form C.pdf

Bonus perks

In addition to your Crowd IPA, you'll receive perks for investing in Canopy.
Invest
$100
Receive
  • 10% OFF Canopy "Starter Kit"
Invest
$250
Receive
  • 25% OFF Canopy "Starter Kit"
86 investors
Invest
$500
Receive
  • 50% OFF Canopy "Starter Kit"
  • Limited (164 left of 250)
55 investors
Invest
$1,000
Receive
  • 1 Canopy "Starter Kit" (to be sent to you or donated to a frontline worker/organization of your choice)
  • Limited (70 left of 125)
19 investors
Invest
$2,000
Receive
  • 2 Canopy "Starter Kits" (to be sent to you or donated to frontline workers/an organization of your choice)
  • Limited (56 left of 75)
5 investors
Invest
$5,000
Receive
  • 3 Canopy "Starter Kits" (to be sent to you or donated to frontline workers/an organization of your choice)
  • Canopy "Swag Bag"
  • Invitation to participate in Town Hall with Canopy founders
  • Limited (20 left of 25)
2 investors
Invest
$10,000
Receive
  • 4 Canopy "Starter Kits" (to be sent to you or donated to frontline workers/an organization of your choice)
  • Canopy "Swag Bag" with handwritten thank you letter
  • 30 min 1:1 call with Canopy founders
  • Receive monthly investor update emails
  • Limited (8 left of 10)
Invest
$25,000
Receive
  • 5 Canopy "Starter Kits" (to be sent to you or donated to frontline workers/an organization of your choice)
  • Canopy "Swag Bag" with handwritten thank you letter
  • 1 hour 1:1 call with Canopy founders
  • Receive monthly investor update emails
  • Limited (5 left of 5)
Invest
$50,000
Receive
  • 6 Canopy "Starter Kits" (to be sent to you or donated to frontline workers/an organization of your choice)
  • Canopy "Swag Bag" with handwritten thank you letter
  • 1 hour 1:1 call with Canopy founders
  • Receive monthly investor update emails
  • Invitation to tour our manufacturing operations in 2021 pending COVID travel restrictions
  • Limited (2 left of 2)

Why others invested

See all reviews (0) See all (0)

Canopy is a transparent respirator solving N95 flaws. It saves hospital over 50% on PPE. Led by Google, Johns Hopkins & Boston Scientific alumni, this investment comes with a $1B / yr enterprise pipeline.

Profile picture of Kathryn Cartini
Kathryn Cartini
Active investor
over 4 years ago

I think the business idea and problem-solving capability of the product are valuable. This investment is also a hedge in the portfolio against the possibility of the pandemic being much longer than we hoped.

Profile picture of Marvill Martin
Marvill Martin
Active investor
over 4 years ago

I work in healthcare so, to me, COVID or not, this product is quite revolutionary. A reusable N95 mask would be such a cost-savings which is so needed in healthcare.

Profile picture of Dawnyetta Reese
Dawnyetta Reese
Active investor
over 4 years ago

About Canopy

Legal Name
Grove Biomedical LLC
Founded
Apr 2020
Form
New York LLC
Employees
0
Website
onecanopy.com
Social Media
Headquarters
Google Map location of of Canopy
282 Katonah Avenue , Katonah, NY
Headquarters
282 Katonah Avenue, Katonah, NY, United States 10536

Canopy Team
Everyone helping build Canopy, not limited to employees

Profile picture of Joe Rosenberg
Joe Rosenberg
Founder & CEO
Featured in Superheroes · Read
A long-time leader on Google's Emerging Business Development team, Joe is an expert in cross-functional innovation, strategic partnerships, retail e-commerce, and enterprise sales.
Profile picture of Doug Clift
Doug Clift
Head of Operations
A biomedical engineer turned operations leader, Doug drives product innovation and supply chain development for Canopy. Previously, Doug managed Operations Innovation for DaVita, a Fortune 200 global kidney dialysis service.
Profile picture of Jim Walker
Jim Walker
Head of Sales and Marketing
For 20 years Jim was the SVP of Global Corporate Sales and led pricing strategy for Boston Scientific. Prior to joining Boston Scientific, Jim was a sales director with Johnson and Johnson.
Profile picture of Qing Xiang Yee
Qing Xiang Yee
Head of Product
QX holds an MS from Johns Hopkins University's Center for Bioengineering Innovation and Design. He's an expert in human-factors engineering, and prior to Canopy spent six years as a senior engineer at Singapore’s national defense research agency.
Profile picture of Jacqueline Terry
Jacqueline Terry
Head of Fulfillment & Logistics
Expertise in Process Management, Hyper Growth, Call Centers, and Operational Planning / Demand Modeling. Global expansion expert, launching products in 20 countries, including AMEA, APAC, and AMER including FDA / regulatory readiness per market.
Profile picture of Narissa Joyner, MD
Narissa Joyner, MD
Lead Clinical Advisor
An Attending Emergency Medicine Physician at Northwell, Narissa has a background in research, emergency medicine, and healthcare. She also happens to be Joe’s neighbor and the inspiration for Canopy.
Profile picture of John Strong
John Strong
Healthcare Strategy
40-year healthcare executive and Bellwether League (healthcare supply chain hall of fame) inductee, John leads Canopy's pricing and market segmentation strategy. Former President and CEO of Consorta, a $5B GPO, and former SVP at $50B GPO Premier.
Profile picture of Kwame Ulmer
Kwame Ulmer
Regulatory Affairs Advisor
A trained engineer who served as Deputy Director at the FDA for 12 years, Kwame has been instrumental in helping Canopy navigate the necessary regulatory path to bring our flagship product to customers safely, thoughtfully, and quickly.
Profile picture of Tom Gsell, PhD
Tom Gsell, PhD
Lead Filtration Advisor
In his 36-year tenure leading Materials R&D for Pall Life Sciences & Industrial divisions, Tom has co-invented over 100 patents, including the groundbreaking process for blood leuko-depletion.
Profile picture of Armin Cline
Armin Cline
Enterprise Healthcare Sales
40 years of sales experienc, including VP of Sales for Covidien / Medtronic. Bring best-in-class medical innovation to healthcare purchasing organizations & key strategic customers.
Profile picture of Kim Rosenberg
Kim Rosenberg
Advisory Board Chair
While leading a $12B institutional retirement business, Kim brings her expertise building new business lines and providing bespoke financial solutions for Fortune 500 companies to Canopy's strategic growth, distribution, and organizational planning.
Profile picture of David Narrow
David Narrow
Life Sciences Advisor
Co-founder & CEO of Sonavex, a commercial stage ultrasound solutions startup, David is Canopy's lead advisor. He has recently been recognized by Forbes 30 Under 30 Healthcare and Baltimore's Top BioHealth Startup CEO in 2019.
Profile picture of Adam Pozdro
Adam Pozdro
Industrial & Graphic Design
Adam's design language touches all aspects of Canopy's physical and digital products. He's top in his class at DAAP, one of the world's top design schools.
Profile picture of Noelle Cassier
Noelle Cassier
Digital Marketing & Community Engagement
Noelle supports Canopy's strategic initiatives across product, distribution and community engagement. She graduated Magna Cum Laude from Duke in May 2020.
Profile picture of Edward Normandin, JD, MBA
Edward Normandin, JD, MBA
Legal Counsel
Profile picture of Howard Hoff, CPA, CGMA
Howard Hoff, CPA, CGMA
Accounting and Advisory
Profile picture of Jennifer McManamey
Jennifer McManamey
Medical Device Risk Management & Insurance
Profile picture of Blair Roth
Blair Roth
Commercialization Manager
Profile picture of Andrew McAleavey
Andrew McAleavey
Patent Agent
Profile picture of Paloma Aelyon
Paloma Aelyon
Storyteller
Profile picture of Kirby Smith
Kirby Smith
User Experience Researcher
Profile picture of Joshua Boggs
Joshua Boggs
Product Designer
Profile picture of Debbie Prenatt
Debbie Prenatt
Sustainability Advisor
Profile picture of Victoria Lee, PhD
Victoria Lee, PhD
Material Science Advisor
Profile picture of John Connolly, EdD
John Connolly, EdD
Physician Engagement Advisor
Profile picture of Amanda Gordon
Amanda Gordon
Customer Experience Advisor
Profile picture of James McGrath, PhD
James McGrath, PhD
Nanoscale Filtration Advisor
Profile picture of Spencer Joynt
Spencer Joynt
Creative Advisor
Profile picture of Garrett DeRossett
Garrett DeRossett
Creative Advisor
26 more team members
Edward Normandin, JD, MBA
Legal Counsel
Joe Rosenberg
Founder & CEO
Howard Hoff, CPA, CGMA
Accounting and Advisory
Doug Clift
Head of Operations
Jennifer McManamey
Medical Device Risk Management & Insurance
Jim Walker
Head of Sales and Marketing
Qing Xiang Yee
Head of Product
Blair Roth
Commercialization Manager
Andrew McAleavey
Patent Agent
Jacqueline Terry
Head of Fulfillment & Logistics
Narissa Joyner, MD
Lead Clinical Advisor
Paloma Aelyon
Storyteller
John Strong
Healthcare Strategy
Kirby Smith
User Experience Researcher
Kwame Ulmer
Regulatory Affairs Advisor
Joshua Boggs
Product Designer
Debbie Prenatt
Sustainability Advisor
Tom Gsell, PhD
Lead Filtration Advisor
Victoria Lee, PhD
Material Science Advisor
Armin Cline
Enterprise Healthcare Sales
Kim Rosenberg
Advisory Board Chair
John Connolly, EdD
Physician Engagement Advisor
David Narrow
Life Sciences Advisor
Amanda Gordon
Customer Experience Advisor
James McGrath, PhD
Nanoscale Filtration Advisor
Adam Pozdro
Industrial & Graphic Design
Noelle Cassier
Digital Marketing & Community Engagement
Spencer Joynt
Creative Advisor
Garrett DeRossett
Creative Advisor

Press

Waccabuc Neighbors Look to Reinvent N95 Respirators
TAPinto TAPinto
·
Jun 21, 2021

WACCABUC, N.Y. - For entrepreneurs like Joe Rosenberg, a once-a-century pandemic presented a unique opportunity to make l...

All-star startup improves N95 design
plasticstoday.com plasticstoday.com
·
May 13, 2021

Canopy is a reusable, transparent respirator designed to address the shortcomings of N95 disposable devices. It is the fl...

Proprietary Copolyester Used in Two COVID-Fighting Applic...
Ptonline
·
May 13, 2021

Two new healthcare-related innovations that use the proprietary amorphous copolyester Tritan from Eastman were spurred on...

Canopy relies on Eastman Tritan copolyester for COVID-fig...
Jhconline
·
May 10, 2021

May 10, 2021 - The world's historic fight against COVID-19 has brought to light many previously hidden pain points impact...

Fast Company World Changing Ideas Awards 2021: Pandemic R...
Fast Company Fast Company
·
May 4, 2021

Programs, products, policies, or anything else designed to mitigate either the health effects of COVID-19 or the economic...

The Startup That's Protecting Our Healthcare Workers
Google Docs Google Docs
·
Feb 11, 2021

A 3-Step Strategy to Support the New U.S. Mask Mandate
Harvard Business Review Harvard Business Review
·
Jan 26, 2021

We couldn't agree more with the Biden administration's plea for Americans to wear masks for 100 days and its mandates tha...

Google, Hopkins, FDA, Pall and Boston Scientific alumni r...
MarketWatch MarketWatch
·
Dec 21, 2020

Google, Hopkins, FDA, Pall and Boston Scientific alumni release Canopy, a transparent reusable respirator to solve N95 cr...

Show all
Logo of Canopy

Canopy

Canopy successfully raised $325,470 from 723 investors on July 1, 2021
Profile picture of Randi Zuckerberg
Profile picture of Uma Aggarwal
Profile picture of Robert Spalding
Profile picture of Kunal Parikh
Profile picture of Marisa Meier
Randi, Uma, Robert, Kunal, Marisa, and 718 others invested. 161 Reviews
Republic

Giving everyone access to early-stage startup investing

For investors
  • Why invest
  • How it works
  • FAQ
  • Risks
  • Privacy policy
  • Accessibility
  • Cookie Preferences
  • Form CRS
For startups
  • Why raise
  • Learn
  • FAQ
  • Instruments
  • Crowd SAFE
  • Tokenized assets
Company
  • About
  • Journal
  • Events
  • Contact
  • We're hiring!
Dollar Refer a startup, get $2,500
Dollar Refer a startup, get $2,500

Invest in the app

Android app iOS app

Invest in the app

Android app iOS app

This site (the "Site") is owned and maintained by OpenDeal Inc., which is not a registered broker-dealer. OpenDeal Inc. does not give investment advice, endorsement, analysis or recommendations with respect to any securities. All securities listed here are being offered by, and all information included on this Site is the responsibility of, the applicable issuer of such securities. The intermediary facilitating the offering will be identified in such offering’s documentation.

All related securities activity is conducted by OpenDeal Broker LLC a registered broker-dealer, Member of FINRA and SiPC, an affiliate of OpenDeal Inc. and OpenDeal Portal LLC, located at 149 5th Avenue, 10th Floor, New York, NY 10010. Please check our background on FINRA’s BrokerCheck.

Certain pages discussing the mechanics and providing educational materials regarding regulation crowdfunding offerings may refer to OpenDeal Broker LLC and OpenDeal Portal LLC collectively as “Republic”, solely for explanatory purposes.

Neither OpenDeal Inc., OpenDeal Portal LLC nor OpenDeal Broker LLC make investment recommendations and no communication, through this Site, or in any other medium, should be construed as a recommendation for any security offered on or off this investment platform. Investment opportunities posted on this Site are private placements of securities that are not publicly traded, involve a high degree of risk, may lose value including the total loss of invested capital, are subject to holding period requirements and are intended for investors who do not need a liquid investment. Past performance is not indicative of future results. Investors must be able to afford the loss of their entire investment. Only qualified investors, who understand the risks of early-stage investment and who meet the Republic's investment criteria may invest. Investors may be restricted to only Accredited Investors or non-U.S. persons, to invest in offerings hosted by OpenDeal Broker. Neither OpenDeal Inc., OpenDeal Portal LLC nor OpenDeal Broker LLC, nor any of their officers, directors, agents and employees make any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy or completeness of any information on this Site or the use of information on this site. Offers to sell securities can only be made through official offering documents that contain important information about the investment and the issuers, including risks. Investors should carefully read the offering documents. Investors should conduct their own due diligence and are encouraged to consult with their tax, legal and financial advisors.

By accessing the Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy. Please also see OpenDeal Broker’s Business Continuity Plan and Additional Risk Disclosures. All issuers offering securities under regulation crowdfunding as hosted by OpenDeal Portal LLC are listed on the All Companies Page. The inclusion or exclusion of an issuer on the Platform Page and/or Republic’s Homepage, which includes offerings conducted under regulation crowdfunding as well as other exemptions from registration, is not based upon any endorsement or recommendation by OpenDeal Inc, OpenDeal Portal LLC, or OpenDeal Broker LLC, nor any of their affiliates, officers, directors, agents, and employees. Rather, issuers of securities may, in their sole discretion, opt-out of being listed on the Platform Page and Homepage.

Investors should verify any issuer information they consider important before making an investment.

Investments in private companies are particularly risky and may result in total loss of invested capital. Past performance of a security or a company does not guarantee future results or returns. Only investors who understand the risks of early stage investment and who meet the Republic's investment criteria may invest.

Neither OpenDeal Inc., OpenDeal Portal LLC nor OpenDeal Broker LLC verify information provided by companies on this Site and makes no assurance as to the completeness or accuracy of any such information. Additional information about companies fundraising on the Site can be found by searching the EDGAR database, or the offering documentation located on the Site when the offering does not require an EDGAR filing.

To help the government fight the funding of terrorism and money laundering activities, Federal law requires all financial institutions to obtain, verify, and record information that identifies each person who opens an account. Therefore, when you use the Services we will ask for your name, address, date of birth, and other information that will allow us to identify you. We may also ask to see your driver's license, passport or other identifying documents.

Republic and its affiliates are not and do not operate or act as a bank. Certain banking services are provided by BankProv, member FDIC / member DIF. FDIC coverage only applies in the event of bank failure. Digital (crypto) assets and investment products are not insured by the FDIC, may lose value, and are not deposits or other obligations of BankProv and are not guaranteed by BankProv. Terms and conditions apply.

Invest in startups using your credit card
You can invest using your credit card

Made in SF/NYC